Advertisement

The nine hole peg test as an outcome measure in progressive MS trials

Published:November 24, 2022DOI:https://doi.org/10.1016/j.msard.2022.104433

      Highlights

      • Redefining the nine hole peg test in progressive MS makes it a more useful outcome.
      • Non-ambulatory MS patients continue to experience nine hole peg test worsening.
      • Our findings suggest that non-ambulatory people with MS can be included in clinical trials.

      Abstract

      Background

      The nine-hole peg test (NHPT) is the outcome measure with the least change in secondary and primary progressive MS (SPMS and PPMS) trials. The Standard NHPT is defined as the average of four measurements, two in each hand. Little is known about the performance of alternative NHPT scoring methods as longitudinal outcome measures in progressive MS. Non-ambulatory people with progressive MS are now generally excluded from clinical trials, and there is little information on longitudinal NHPT change in this patient group. In this investigation, we used patient-level data from two large randomized controlled trials in progressive MS to explore alternative NHPT scoring methods and NHPT change in non-ambulatory people with progressive MS.

      Methods

      We used patient-level data from the ASCEND (SPMS, n = 889) and PROMISE (PPMS, n = 943) clinical trials to compare significant change on the Standard NHPT with the alternatives dominant hand (DH), non-dominant hand (NDH), and either hand (EH) NHPT in ambulatory and non-ambulatory trial participants.

      Results

      The Standard NHPT changed slowly and showed few worsening events, as did the DH and NDH alternatives. Using the EH NHPT resulted in a substantial increase of worsening events. Non-ambulatory trial participants with PPMS experienced more NHPT worsening than ambulatory participants, especially when using the EH NHPT.

      Conclusion

      Using the EH NHPT yielded substantially more worsening events in people with progressive MS. Clinical trials in non-ambulatory people may be possible with the NHPT as the primary outcome measure. More research into the precision of these measures in this patient group is necessary.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ebers G.C.
        • Heigenhauser L.
        • Daumer M.
        • et al.
        Disability as an outcome in MS clinical trials.
        Neurology. 2008; 71: 624-631https://doi.org/10.1212/01.wnl.0000313034.46883.16
        • Feys P.
        • Lamers I.
        • Francis G.
        • et al.
        The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis.
        Mult. Scler. 2017; 23: 711-720https://doi.org/10.1177/1352458517690824
        • Fischer J.S.
        • Jak A.J.
        • Kniker J.E.
        • et al.
        Multiple Sclerosis Functional Composite (MSFC): Administration and Scoring Manual.
        National Multiple Sclerosis Society, New York2001
        • Hoogervorst E.L.J.
        • Kalkers N.F.
        • Cutter G.R.
        • et al.
        The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite.
        Mult. Scler. 2004; 10: 55-60
        • Kapoor R.
        • Ho P.-.R.
        • Campbell N.
        • et al.
        Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
        Lancet Neurol. 2018; 17: 405-415https://doi.org/10.1016/S1474-4422(18)30069-3
        • Koch M.W.
        • Cutter G.R.
        • Giovannoni G.
        • et al.
        Comparative utility of disability progression measures in PPMS Analysis of the PROMiSe data set.
        Neurol Neuroimmunol. Neuroinflamm. 2017; 4: e358https://doi.org/10.1212/NXI.0000000000000358
        • Koch M.W.
        • Mostert J.
        • Repovic P.
        • et al.
        Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis.
        Neurology. 2021; 96: e111-e120https://doi.org/10.1212/WNL.0000000000011123
        • Koch M.W.
        • Mostert J.
        • Uitdehaag B.
        • Cutter G.
        Clinical outcome measures in SPMS trials: an analysis of the IMPACT and ASCEND original trial data sets.
        Mult. Scler. 2020; 26: 1540-1549https://doi.org/10.1177/1352458519876701
        • Koch M.W.
        • Mostert J.P.
        • Uitdehaag B.
        • Cutter G.
        A comparison of clinical outcomes in PPMS in the INFORMS original trial data set.
        Mult. Scler. 2021; 27: 1864-1874https://doi.org/10.1177/1352458520987539
        • Kragt J.J.
        • van der Linden F.A.H.
        • Nielsen J.M.
        • et al.
        Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis.
        Mult. Scler. 2006; 12: 594-598
        • Kurtzke J.F.
        Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).
        Neurology. 1983; 33: 1444-1452
        • Motl R.W.
        • Cohen J.A.
        • Benedict R.
        • et al.
        Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.
        Mult. Scler. 2017; 23: 704-710https://doi.org/10.1177/1352458517690823
        • Roxburgh R.H.S.R.
        • Seaman S.R.
        • Masterman T.
        • et al.
        Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.
        Neurology. 2005; 64: 1144-1151https://doi.org/10.1212/01.WNL.0000156155.19270.F8
        • Schwid S.R.
        • Goodman A.D.
        • McDermott M.P.
        • et al.
        Quantitative functional measures in MS: what is a reliable change?.
        Neurology. 2002; 58: 1294-1296
        • Solaro C.
        • Cattaneo D.
        • Brichetto G.
        • et al.
        Clinical correlates of 9-hole peg test in a large population of people with multiple sclerosis.
        Mult. Scler. Relat. Disord. 2019; 30: 1-8https://doi.org/10.1016/j.msard.2019.01.043
        • Solaro C.
        • Grange E.
        • Di Giovanni R.
        • et al.
        Nine Hole Peg Test asymmetry in refining upper limb assessment in multiple sclerosis.
        Mult. Scler. Relat. Disord. 2020; 45102422https://doi.org/10.1016/j.msard.2020.102422
        • Wolinsky J.S.
        • Narayana P.A.
        • O'Connor P.
        • et al.
        Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
        Ann. Neurol. 2007; 61: 14-24https://doi.org/10.1002/ana.21079